Navigation Links
Laboratory detective work points to potential therapy for rare, drug-resistant cancer
Date:2/12/2014

PITTSBURGH, Feb. 13, 2014 University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.

By screening a library of FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, UPCI scientists were surprised when they found several potential possibilities to try if the cancer becomes resistant to standard drug treatment.

The discovery, which will be published in the February 15th issue of Cancer Research, demonstrates that high-throughput screening of already FDA-approved drugs can identify new therapies that could be rapidly moved to the clinic.

"This is known as 'drug repurposing,' and it is an increasingly promising way to speed up the development of treatments for cancers that do not respond well to standard therapies," said senior author Anette Duensing, M.D., assistant professor of pathology at UPCI. "Drug repurposing builds upon previous research and development efforts, and detailed information about the drug formulation and safety is usually available, meaning that it can be ready for clinical trials much faster than a brand-new drug."

Dr. Duensing and her team ran the screening on 89 drugs previously approved by the FDA in an attempt to find more treatment options for patients with gastrointestinal stromal tumors (GISTs), which are uncommon tumors that begin in the walls of the gastrointestinal tract. According to the American Cancer Society, about 5,000 cases of GISTs occur each year in the United States with an estimated five-year survival rate of 45 percent in patients with advanced disease.

GISTs are caused by a single gene mutation and can be successfully treated with the targeted therapy drug imatinib, known by the trade name Gleevec. However, about half of the patients treated with Gleevec become resistant to the drug within the first two years of treatment.

After studying how samples of GIST responded to various concentrations of the 89 drugs in the laboratory, Dr. Duensing and her colleagues identified 37 compounds that showed some anticancer activity in at least one of the concentrations tested. Importantly, they noted that the most promising candidates all belonged to only two major drug classes: inhibitors of gene transcription and so-called topoisomerase II inhibitors. Based on these findings, the research team selected the two most promising compounds for further testing gene transcription inhibitor mithramycin A, which is in clinical trials to treat Ewing sarcoma, and topoisomerase II inhibitor mitoxantrone, which is used in metastatic breast cancer and leukemia.

Both drugs were highly effective in fighting GIST in laboratory tests. Moreover, the mechanism of action of each drug was linked to the specific underlying biology of these tumors.

"These are very encouraging results," said Dr. Duensing. "The next step will be moving our findings to clinical exploration to see if the results we found in the lab hold up in patients."


'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Related biology news :

1. From surgery to laboratory and back again
2. Story tips from the Department of Energys Oak Ridge National Laboratory, February 2014
3. Story tips from the Department of Energys Oak Ridge National Laboratory, January 2014
4. Official opening of wildlife health genetic and forensic laboratory between EcoHealth Alliance and Sabah Wildlife Department
5. New book on mouse models of cancer from Cold Spring Harbor Laboratory Press
6. New book on calcium techniques from Cold Spring Harbor Laboratory Press
7. New book on Signaling by Receptor Tyrosine Kinases by Cold Spring Harbor Laboratory Press
8. New manual from Cold Spring Harbor Laboratory Press on culturing neural cells
9. New eye treatment effective in laboratory tests
10. Medbox Partners with Licensed Medical Cannabis Laboratory and Cultivation Center in Canada
11. Mount Sinai researchers develop first successful laboratory model for studying hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Laboratory detective work points to potential therapy for rare, drug-resistant cancer
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... ... 15, 2017 , ... Kenall, a leader in sealed solid-state ... tightly sealed and perform efficiently for years. The downlights are ideal for a ... enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical ...
(Date:8/14/2017)... Oregon (PRWEB) , ... August 14, 2017 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the release ... , SYZYGY is intended to satisfy the need for a compact, low cost, ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There is ... more natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third Wave ... established manufacturing presence and know-how of Biorigin will allow us to bring truly ...
(Date:8/10/2017)... ... August 09, 2017 , ... Okyanos Center for Regenerative ... at the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, 2017. This ... , With oversight from the Ministry of Health’s National Stem Cell Ethics Committee ...
Breaking Biology Technology: